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Introduction: No clear data are available on the high rate of tobacco-
independent lung cancer in women. We hypothesize that genetic 
events or hormonal factors may be partly involved.
Methods: We aimed to compare clinical, pathological, and biological 
characteristics of lung cancer in two cohorts of women: smokers and 
never-smokers. A total of 140 women (63 never-smokers and 77 former/
current smokers) with adenocarcinoma, were included in this study.
Results: The never-smokers were characterized by a higher age 
(67 versus 58.7 years; p < 0.0001) and a higher frequency of lepidic 
features (60.3% versus 37.7%; p = 0.008) compared with smokers. 
We observed differential genetic alteration repartition in women 
according to their tobacco status: 50.8% of never-smokers displayed 
an epidermal growth factor receptor (EGFR) mutation versus 10.4% 
of smokers (p < 0.001). In contrast, K-Ras was more frequently 
mutated in smokers (33.8%) than in never-smokers (9.5%; p = 0.001). 
We also observed a higher percentage of estrogen receptors (ER) α 
expression (p = 0.03; and p = 0.008 with two different antibodies) in 
patients who never smoked when compared with smokers. There was 
no significant difference in ERβ and progesterone receptors between 
the groups. Finally, ERα expression was correlated with the presence 
of an EGFR mutation.
Conclusions: This study suggests that when lung cancer occurs in 
women who have never smoked, it is more frequently associated with 
an EGFR mutation and ERα expression, with a correlation between 
both markers. These findings underline the possibility of treating 
women who have never smoked by targeting both hormonal factors 
and genetic abnormalities.
Key Words: Epidermal growth factor receptor, Estrogen receptor, 
K-Ras, Non–small-cell-lung-cancer, Tobacco.
(J Thorac Oncol. 2013;8: 923-929)
The incidence of lung cancer in women affects an estimated 516,000 women worldwide, of which 100,000 are in the 
United States and 70,000 in Europe.1 Lung cancer is now the 
fourth most frequent cause of death from cancer worldwide, 
and the first cause in the United States and some European 
countries. These epidemiological data underline that cancer in 
women deserves specific attention.
Until now, lung cancers occurring in women have been 
treated similarly to lung cancers in men. However, numer-
ous studies have highlighted different characteristics of lung 
cancer in women. We along with others have described the 
specificities of clinical and radiological presentations, pathol-
ogy types, the response-to-cancer treatments, and patient out-
comes in women.2,3 Besides these clinical observations, other 
research has added new data that reinforce the specificities of 
lung cancer in women.
Two main mechanisms have emerged from recent find-
ings on lung carcinogenesis in women: the high prevalence of 
genetic alterations, such as epidermal growth factor receptor 
(EGFR) mutations,4,5 and the potential involvement of hor-
monal factors.6 EGFR seems to be more frequently mutated 
in women than in men, leading to a better response rate to 
EGFR-tyrosine kinase inhibitor (TKI) therapy.7 Recent epi-
demiological and clinical studies have provided evidence of a 
role for estrogens in the genesis and progression of lung can-
cer, especially non–small-cell lung tumors.6,8
Preclinical studies have shown a solid rationale for 
the crucial involvement of hormones in lung carcinogenesis. 
Many hormonal receptors, such as ERα, ERβ (estrogen 
receptors α and β), and PR (progesterone receptors) have been 
isolated from lung cancer tissues. We have recently reported 
a higher expression of ERs in women operated on for lung 
cancer compared with men.9 Moreover, ERs have been shown 
to be involved in the onset of lung cancer in cells and animal 
models.10 Last, the interaction of ERs with growth factor 
receptor signaling, including EGFR, has been demonstrated.11 
A direct correlation between both pathways has been also 
suggested by two recent studies,12,13 indicating that lung cancer 
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treatment could include both EGFR- and hormone-targeting 
drugs.14
Tobacco smoking is the main cause of lung cancer. 
However, lung cancer also occurs in people who have never 
smoked, and it ranks as the seventh most common cause of 
cancer death worldwide.15,16 Lung cancer in never-smokers 
is more frequently observed in women, representing 20% 
to 70% of these cases, according to geographical origin and 
patient selection.17 Lung cancer in never-smokers is also char-
acterized by a higher rate of gene mutations, involving EGFR, 
HER2, or PI3K, and of EML4–ALK translocations. We have 
recently identified, in a national collaborative study, other 
genetic abnormalities in this population.18 Nevertheless, no 
clear data are available to improve our understanding of the 
higher rate of tobacco-independent lung cancer in women.
We hypothesize that genetic events or hormonal fac-
tors may be part of this observation. Herein, we have aimed 
to compare clinical and pathological characteristics of lung 
cancer in two cohorts of women smokers and women never-
smokers, with a specific focus on driver oncogenes and hor-
monal receptors.
PATIENTS AND METHODS
Patients and Tissues
Tumor specimens were collected from 50 women who 
underwent surgery at the Thoracic Oncology Department 
(Toulouse University Hospital, France; this comprised the 
Ligue collection). A second collection of 90 tumor samples 
was collected from the Lung Genes (LG-collection) study, 
which involved 13 centers in France.18 Only women were 
included in this study, and all patients had been treated with 
surgery.
We collected specific tobacco-exposure status from all 
women by checking each patient’s file and subsequently per-
forming a telephone- or mail-based survey. The 63 patients 
who had never smoked were defined according to current 
guidelines19 as persons with lifetime exposure of less than 100 
cigarettes.
A lung cancer pathologist assessed the diagnoses by 
applying the latest World Health Organization classification,20 
and the clinicopathological stage was assigned according to 
the tumor, node, metastasis (TNM) classification.21 Patients 
who were included before the last classification were reclassi-
fied, especially for lepidic components. All patients signed an 
informed consent permitting analysis of tissues. Patients were 
treated and follow-up was done at our institutions, to ensure 
collection of clinical data.
Immunohistochemistry
We selected the most relevant antibodies8,10,13,22,23 from 
the literature (Fig. 1 and Table 1). We chose the N-terminal 
ERα (1D5 clone DAKO) and the PR (PgR 636 clone DAKO) 
used in breast carcinoma because of their therapeutic implica-
tions. A C-terminal α-ER monoclonal antibody (clone sc-8002 
F10; Santa-Cruz Biotechnology, Dallas, TX) and an ERβ 
 polyclonal rabbit antibody (Biogenex, Fremont, CA) were also 
chosen because of their supposed prognostic implications.9
Samples (5-µm sections) of lung tumor tissue were 
mounted on positively charged slides and dried for 1 hour at 
60°C before they underwent immunohistochemical assays for 
ERα, ERβ, and PR expression. We used the PT link pretreat-
ment module (DAKO, Carpentaria, CA), which allows the 
entire pretreatment process of deparaffinization, rehydration, 
and epitope retrieval to be combined in a three-in-one speci-
men-preparation procedure.
The slides were treated with 3% hydrogen peroxide to 
block endogenous peroxidase activity. Nonimmune serum 
was used to block nonspecific staining. Antigen retrieval 
was achieved by proteinase K digestion for 10 minutes, and 
the primary antibody was applied at a dilution of 1:50, and 
then incubated for 2 hours at room temperature. Biotinylated 
secondary antimouse antibodies (1:100) were applied to the 
sections for 20 minutes. Visualization was obtained, using 
the labeled streptavidin–biotin staining method (LSAB kit; 
DAKO). We then evaluated staining intensity, its nuclear or 
FIGURE 1.  Immunohistochemistry of hormonal tumor stain-
ing (scale magnitude ×400). A, ERα staining of lung tumor 
tissue (× 400) (F10). Nucleus score is +++, cytoplasm score is 
++; (B), ERβ staining of lung tumor tissue (× 400). ERβ score is 
6 (A). ER, estrogen receptor.
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cytoplasmic localization, and the proportion of positively 
stained cells. We used semiquantitative scores for nuclear and 
cytoplasmic staining: that is, mild (+), moderate (++), and 
high (+++).
For all hormonal receptors, we applied the same score 
as used in breast cancer, with a 10% positive-cell threshold.24 
However, for estrogen,β receptors there is no currently 
validated score, so we applied a published proportion score.23 
For this score, we used a high-score class (6–8) and a low-
score class (0–4) by adding the proportion of positively 
stained cells (five scores from 1–5) and one of the three 
intensity scores (1–3).
Molecular Analysis of EGFR and K-Ras
For EGFR and K-Ras, direct sequencing was per-
formed after polymerase chain reaction amplification of 
TABLE 1.  Antibody Staining and Scores
ERα 1D5 and F10, Breast Cancer Score 0 0%–10% of Tumoral Cells Stained
1 >10% of tumoral cells stained
ERα 1D5 nucleus intensity 0 No staining
+ Low staining
++ Medium staining
+++ High staining
ERα 1D5 cytoplasm score 0 0%–10% of tumoral cells stained
1 10–50% of tumoral cells stained
2 >50% of tumoral cells stained
ERα 1D5 cytoplasm intensity 0 No staining
+ Low staining
++ Medium staining
+++ High staining
ERα F10 nucleus score 0 0%–10% of tumoral cells stained
1 >10% of tumoral cells stained
ERα F10 nucleus intensity 0 No staining
+ Low staining
++ Medium staining
+++ High staining
ERα F10 cytoplasm intensity 0 No staining
+ Low staining
++ Medium staining
+++ High staining
ERβ score % of stained nucleus 1 0%–1% of nucleus staining in tumoral cells
2 1%–10%
3 10%–30%
4 30%–70%
5 70%–100%
ERβ score intensity staining 0 No staining
1 Low staining
2 Medium staining
3 High staining
Score of 0–8 = Score % of Stained Nucleus + Score Intensity Staining
0 C Low expression
ERβ score 1 C Low expression
2 C Low expression
3 C Low expression
4 B Medium expression
5 B Medium expression
6 A High expression
7 A High expression
8 A High expression
ER, estrogen receptor.
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EGFR exons 18, 19, 20, 21 (NM_005228.3), and K-Ras 
exons 2 and 3 (NM_033360.2). Purified DNA was sequenced 
using a BigDye Terminator Cycle Sequencing Kit (Applied 
Biosystems, Foster City, CA). Sequencing reactions were 
analyzed on a 16-capillary ABI3130 or a 48-capillary 3730 
DNA analyzer in both sense and antisense directions, from at 
least two independent amplifications. Sequence reading and 
alignment were performed with SeqScape software (Applied 
Biosystems).
Statistics
Continuous variables are presented by their means ± 
standard deviations. We first described and compared the 
patients’ characteristics between our local series and the 
national collection. Second, we tested whether the associa-
tion between smoking status and the patients’ characteristics 
depended on where the data were collected from; we did 
not observe any significant interaction between the patients’ 
characteristics and the place of collection. We subsequently 
decided to pool data from both these series for the final anal-
ysis. The patients’ characteristics were compared between 
smokers and nonsmokers. The ÷2 or Fisher’s exact test was 
used to compare categorical variables, and Student’s t test 
or a nonparametric Wilcoxon test was used for continuous 
variables. We estimated Spearman’s correlation coefficients 
(ñ) between each biological characteristic and tested the null 
hypothesis (ñ = 0) using a Benjamini–Yekutieli correction for 
multiple tests. All analyses were conducted using Stata SE 
version 11.2.
RESULTS
Clinical and Pathological Characteristics of 
Lung Cancer in Women Never-Smokers
A total of 140 women with adenocarcinoma (AC) were 
included in this study. Of these, 63 were never-smokers and 
77 were former or current smokers. We double-checked this 
status by collecting data from the patients’ files and by send-
ing a specific survey to each patient to ensure that she ful-
filled the abovementioned criteria. We compared both groups 
(Table 2) and did not observe any significant differences 
regarding either TNM status or tumor stage. In contrast, 
we observed a higher average age at disease appearance for 
women who never smoked (67 years) compared with smok-
ers (58.7 years; p < 0.0001). In addition, lepidic features 
were more frequent in the never-smokers (60.3% versus 
37.7%; p = 0.008).
Genetic Characteristics of lung Cancer 
in Women Never-Smokers
For all patients, we assessed the mutational status of 
EGFR (exon 19 and 21) and K-Ras (exon 2). Patients with a 
mutated EGFR represented 28.6% of the overall population in 
this study. More precisely, 50.8% of never-smokers displayed 
the mutation compared with 10.4% of former or current 
smokers (p < 0.001; Table 3). In contrast, the K-Ras mutation 
was more frequent in smokers (33.8%) compared with never-
smokers (9.5%; p = 0.001) (Fig. 2).
Hormone-Receptor Expression in Women  
Never-Smokers
We analyzed the ERα, ERβ, and the PR for all patients 
using immunohistochemistry. For all markers, we analyzed 
the percentage of positive cells and the intensity of staining in 
both cytoplasm and the nucleus.
We analyzed ERα expression according to the breast 
cancer testing procedure, as previously described,9 but we 
also extended our analysis to include other parameters, such 
as cytoplasm expression and intensity staining. Moreover, 
we used two different antibodies directed against ERα, as 
described in the literature9: ERα 1D5 (epitopes NH2 terminal) 
used in breast cancer diagnosis and ERα F10sc8002 (epitopes 
COOH terminal)9,13 (Table 1).
For the breast cancer–derived procedure (threshold of 
10% nucleus staining with 1D5 antibody), 11.1% of the never-
smokers and 3.9% of smokers (p = 0.11) had a positive score 
(Table 3). We hypothesize that this score might be inappropriate 
for lung cancer, so we also looked for other parameters. We found 
that both the 1D5 nucleus and the intensity of cytoplasm staining 
were significantly higher in never-smokers versus smokers (p = 
0.008 and p = 0.03, respectively). Using the ERα F10 antibody, 
we observed a higher percentage of positive tumor samples (as 
for the breast cancer score) for never-smokers compared with 
smokers, 23.8% versus 10.4%, respectively (p = 0.03). In sum-
mary, we observed significant differences in nucleus-intensity 
staining with both antibodies for ERα according to the tobacco 
status of women with NSCLC (Table 3 and Fig. 2).
For ERβ we used a polyclonal rabbit antibody.23 We 
observed 100% expression of ERβ in never-smokers com-
pared with 92% in smokers, but ERβ nuclear expression was 
not significantly different (p = 0.12). Last, we analyzed PR 
expression and found a very low rate of expression in both 
populations, with no significant differences (Table 3).
Correlations between Biological Data
We found a negative correlation between the K-Ras and 
EGFR mutations in this female population. Both mutations 
TABLE 2.  Clinical and Pathological Characteristics of 
Women Who Have Never Smoked (n = 63) Versus Female 
Smokers (n = 77)
Never Smoked Smokers p
% of total 45.0% 55.0% —
Age (average) (yr) 67.0 ± 9.7 58.7 ± 9.8 <0.0001
Stage as % of total
 IA 23.8% 29.9% 0.35
 IB 39.7% 22.1% —
 IIA 3.2% 2.6% —
 IIB 9.5% 10.4% —
 IIIA 19.0% 23.4% —
 IIIB 4.8% 10.4% —
 IV 0.0% 1.3% —
Lepidic component (%) 60.3% 37.7% 0.008
Tumor size (average, mm) 33.9 ± 15.4 36.1 ± 22.2 0.85
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remain mutually exclusive for all patients. Interestingly, 
ERα nucleus-intensity staining (of both antibodies) corre-
lated significantly with the EGFR mutation status of all the 
women in the study (Table 4). We did not find any correla-
tion between biomarkers according to smoking status (data 
not shown).
DISCUSSION
Herein, we have aimed to identify the specificities 
of lung cancer in women. We first report that lung cancer 
was similar regarding TNM status at the time of diagnosis. 
We found that lung cancer appeared later in women who 
had never smoked than in women who smoked. These data 
are consistent with a recent study performed in France on 
primary lung cancer.25 An explanation for this might be that 
women are more sensitive to tobacco than men, and that lung 
cancer occurs earlier in this population. The diagnostic age of 
58.7 years for women smokers is lower than the median age 
observed for men smokers. We also observed in our former 
study that women displayed lung cancer at 58 years (compared 
with 61.2 years for men).9 In contrast, women not exposed to a 
carcinogen such as tobacco developed lung cancer later.
We looked at the genetic profiles of both our popula-
tions and found that lung cancer had mutated EGFR more fre-
quently and mutated K-Ras less frequently in women who had 
never smoked. These results are in line with already published 
data. EGFR is known to be mutated in 14% of women smok-
ers compared with 55% who had never smoked.26 Moreover, 
EGFR is more frequently mutated in never-smokers.27 Overall, 
women who had never smoked represented a population char-
acterized by a high probability of EGFR mutation. This finding 
is associated with a better response to EGFR-TKI as reported 
in many recent trials.7,28 Interestingly, we observed that EGFR 
was mutated in 10% of female smokers, suggesting that 
screening for EGFR mutations should not be limited to never-
smokers. K-Ras was mutated in more than 33% of female 
smokers (whereas only 9.5% women who had never smoked 
were affected). K-Ras is known to be mutated by tobacco car-
cinogens, and remains difficult to inhibit by targeted therapy, 
but drugs such as mitogen-activated ERK kinase inhibitors are 
currently being tested.29 Overall, these results show that more 
than 50% of women displayed either EGFR or K-Ras muta-
tions that can be targeted by dedicated drugs. It would be of 
interest to obtain information on other biomarkers, such as 
TABLE 3.  Biological Characteristics of Women Who Have Never Smoked (n = 63) Versus Female Smokers (n = 77)
Never Smoked Smokers p
EGFR mutation as % of each subgroup 50.8% 10.4% <0.001
K-Ras mutation as % of each subgroup 9.5% 33.8% 0.001
ERα nucleus (1D5), % positive/ breast score 11.1% 3.9% 0.11
ER α nucleus (1D5), staining intensity,
 0 69.8% 89.6% 0.008
 + 20.6% 9.1% —
 ++ 9.5% 1.3% —
 +++ 0.0% 0.0% —
ERα nucleus (F10), % positive/ breast score 23.8% 10.4% 0.03
ERα nucleus (F10), staining intensity,
 0 54.0% 75.3% 0.04
 + 28.6% 18.2% —
 ++ 14.3% 5.2% —
 +++ 3.2% 1.3% —
ERβ score
 0 0.0% 7.8% 0.02
 1–8 100% 92.2 %
ERβ nucleus staining intensity
 0 50.8% 38.2% 0.12
 + 38.1% 38.2% —
 ++ 11.1% 23.7% —
 +++ 0.0% 0.0% —
PR nucleus % positive/score 1.6% 0.0% 0.45
PR nucleus staining intensity
 0 85.7% 92.2% 0.25
 + 7.9% 5.2% —
 ++ 0.0% 1.3% —
 +++ 0.0% 0.0% —
EGFR, epidermal growth factor receptor; ER, estrogen receptor; PR, progesterone 
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Her2, BRaf, Pi3K, and EML4–ALK, which are known to be 
deregulated in lung cancer. Unfortunately, we were not able to 
test these biomarkers at the time of this study.
We found higher expression of both ERα and ERβ in 
female never-smokers. ERs α and β are expressed in normal 
lung cells (cultured normal lung fibroblast cell lines and 
normal bronchial epithelial cells) and in the lung tumors of 
both men and women.10 Several in vitro and in vivo studies 
have provided evidence supporting a biological role for 
estrogens in lung carcinogenesis by directly promoting cell 
proliferation. Estrogens stimulate the proliferation of NSCLC 
through ER-mediated signaling, whereas antiestrogens inhibit 
the growth of NSCLC cells.10,14 We, along with others, have 
previously reported that Erα, and to a lesser extent, ERβ, 
was more frequently overexpressed in women than in men, 
and in never-smokers than in smokers. Nose et al.12 reported 
a clear correlation between ERβ and the nonsmoking status 
(p < 0.001) in univariate analysis. Nevertheless, the 
multivariate analysis failed to show any statistical difference 
for ERβ expression according to the sex (p = 0.378) and the 
smoking status (p = 0.294). However, the difference in ER 
expressions according to the smoking status of women has not 
been addressed by the authors. we report here for the first time 
the difference between female never-smokers and smokers.9,13 
These data suggest that oncogenesis in never-smokers relies 
more frequently on hormonal pathways.
There are many reports on the immunohistochemical 
expression of hormonal receptors. Most data are conflicting 
because of two ER isoforms (α and β), the presence of truncated 
forms of ERα, the range of antibodies used, and the absence of 
a validated threshold or score. Thus, we selected specific anti-
bodies that targeted both COOH-terminal and NH
2
-terminal 
ERα and ERβ. We also used previously published scores; for 
ERα, we applied the same scores used in breast cancer, with a 
10% positive-cell threshold and distinguished ER expression 
in the cytoplasm and the nucleus. Last, we used two antibodies 
for ERα staining, 1D5, targeting N-terminal part of the recep-
tor, and F10, targeting the COOH part of the receptor. We first 
applied the breast cancer score with both antibodies and found 
a statistical difference by using 1D5 antibody and not the F10 
antibody. Looking at nuclear intensity staining, we observed a 
statistical difference for both antibodies. Overall, our data sug-
gest that a different score should be used in lung cancer when 
comparing it with breast cancer and that an antibody target-
ing its COOH part is probably more potent in identifying ERα 
expression in lung cancer. For ERβ, there is currently no vali-
dated score, and we used a proportion score.23 Establishment of 
a dedicated score for ER in lung cancer is warranted to ensure 
homogeneity between data and studies.
Stabile et al.12 reported that EGFR protein expression 
was up-regulated in response to antiestrogens in vitro, and 
that ERβ expression was decreased in response to epidermal 
growth factor and increased in response to gefitinib. In addi-
tion, in line with our results, two previous studies also reported 
an association between ERα and ERβ expression and EGFR 
mutations. Raso et al.13 reported the correlation between 
EGFR mutation and ERα expression in a population of ACs, 
27 (in both men and women) of which were found with muta-
tions. Nose et al.12 also reported the correlation between ERβ 
expression and EGFR mutation in a large population of ACs. 
To date, our work is the largest study showing this interaction 
0
10
20
30
40
50
60
70
80
90
100
EGFRm KRASm ERα - ERα +/++/+++ PR - PR +/++/+++
Nucleus F10 Nucleus
FIGURE 2.  Biomarker incidence 
in women who have never smoked 
(shaded) versus women smokers 
(lined). p < 0.001 for EGFR mutation, 
p = 0.001 for K-Ras mutation, and 
p = 0.008 for ERα. EGFR, epidermal 
growth factor receptor; ER, estrogen 
receptor; PR, progesterone receptors.
TABLE 4.  Biomarker Correlations for all Women in the Trial
Mutant  
EGFR
Mutant  
K-Ras
EGFR mutation % of total 1 —
K-Ras mutation −0.35 1
ERα nucleus (1D5), % positive/breast score 0.01 −0.02
ERα nucleus (1D5), staining intensity 0.28 −0.13
ERα nucleus (F10), % positive/ breast score 0.23 −0.11
ERα nucleus (F10), staining intensity 0.30 −0.09
ERβ score −0.13 −0.09
ERβ nucleus staining intensity −0.17 −0.06
PR nucleus % positive/score −0.05 0.16
PR nucleus staining intensity 0.10 0.03
Bold font shows a significant correlation, Benjamini–Yekutieli: p < 0.001.
EGFR, epidermal growth factor receptor; ER, estrogen receptor; PR, progesterone 
receptor.
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in a specific population. Recently, Garon et al.30 reported the 
potential synergy of EGFR inhibitors and ER antagonists on 
preclinical models. Traynor et al.31 reported the result of a pilot 
study where postmenopausal women diagnosed with NSCLC 
were treated with gefitinib and fulvestrant. An ongoing clini-
cal trial (NCT01556191) in France is testing the combination 
of EGFR inhibitors and fulvestrant.
Overall, our study suggests that lung cancer in women 
who have never smoked is more frequently associated with 
EGFR mutations and ERα overexpression and that both bio-
markers are associated. These findings underline the possibil-
ity of treating women who have never smoked with drugs to 
target hormonal factors, genetic abnormalities, or both.
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